These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8573451)
1. Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME J Natl Cancer Inst Monogr; 1995; (17):37-42. PubMed ID: 8573451 [TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
3. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104 [TBL] [Abstract][Full Text] [Related]
4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
7. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Julian-Reynier C; Eisinger F; Moatti JP; Sobol H Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786 [TBL] [Abstract][Full Text] [Related]
8. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733 [TBL] [Abstract][Full Text] [Related]
9. Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. Ackermann S; Lux MP; Fasching PA; Strissl P; Renner SP; Poehls U; Bender HG; Beckmann MW Eur J Cancer Prev; 2006 Dec; 15(6):474-9. PubMed ID: 17106324 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846 [TBL] [Abstract][Full Text] [Related]
11. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499 [TBL] [Abstract][Full Text] [Related]
12. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Ardern-Jones A; Kenen R; Eeles R Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973 [TBL] [Abstract][Full Text] [Related]
13. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607 [TBL] [Abstract][Full Text] [Related]
14. Prophylactic bilateral mastectomy: patterns of practice. Metcalfe KA; Goel V; Lickley L; Semple J; Narod SA Cancer; 2002 Jul; 95(2):236-42. PubMed ID: 12124821 [TBL] [Abstract][Full Text] [Related]
15. [Genetic test and prophylactic treatment in breast cancer families]. Miyoshi Y; Noguchi S Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic mastectomy. Zakaria S; Degnim AC Surg Clin North Am; 2007 Apr; 87(2):317-31, viii. PubMed ID: 17498529 [TBL] [Abstract][Full Text] [Related]
17. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Stolier AJ; Corsetti RL Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474 [TBL] [Abstract][Full Text] [Related]
18. Predictors of and satisfaction with bilateral prophylactic mastectomy. Stefanek ME; Helzlsouer KJ; Wilcox PM; Houn F Prev Med; 1995 Jul; 24(4):412-9. PubMed ID: 7479633 [TBL] [Abstract][Full Text] [Related]
19. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW Breast J; 2004; 10(6):475-80. PubMed ID: 15569201 [TBL] [Abstract][Full Text] [Related]
20. Screening for genetic risk of breast cancer. Rosenthal TC; Puck SM Am Fam Physician; 1999 Jan; 59(1):99-104, 106. PubMed ID: 9917577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]